Aurobindo Pharma Limited has informed the Exchange about Classification of Unit-I of Eugia Pharma Specialities Limited, wholly owned subsidiary of the Company as OAI.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
US FDA inspected Unit-I of Eugia Pharma Specialities Ltd (a wholly owned subsidiary) from February 16-27, 2026. The inspection concluded with 4 observations, and FDA has now classified the facility as "Official Action Indicated" (OAI). This classification indicates FDA's intent to take regulatory action, which could potentially include import alerts or warning letters affecting product supply to the US market. The company states there is no impact on financials or operations currently and is committed to maintaining quality manufacturing standards.
OAI classification is a serious regulatory concern for a pharma company dependent on US revenues. While the company claims no current financial impact, OAI status often precedes import bans or product holds, which could materially affect future exports and approvals from this facility.